18.04.2021
Andritz: International technology Group Andritz has successfully started up a new 500 t/d Herb chemical recovery boiler at Kuantum Papers Limited in Saila Khurd, Hoshiapur district in the state of Punjab, India. The boiler is designed to handle a mixture of hardwood and agro-based black liquor and enables environmentally friendly and more energy-efficient operation compared to a conventional boiler with direct contact evaporator. Thus, the mill’s pulp production as well as the power-to-heat-ratio are substantially increased. The boiler also features a unique vertical air system to minimize air emissions.
Andritz: weekly performance:
-1.21%
Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that out of the initially enrolled 64 patients, all 62 patients included in the treatment cycles have now concluded the Phase II clinical trial e
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 15, 2021 07:00 ET | Source: FibroGen, Inc FibroGen, Inc San Francisco, California, UNITED STATES
SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD). Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in two Phase 3 trials for the treatment of DMD.
Chikungunya Vaccine Candidate: Valneva completes recruitment for Phase 3 trial outbreaknewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outbreaknewstoday.com Daily Mail and Mail on Sunday newspapers.
Published: Apr 13, 2021
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for AK-OTOF, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss. Akouos anticipates that it will submit an investigational new drug application (IND) for AK-OTOF in the first half of 2022.
Otoferlin gene (
OTOF gene. The
OTOF gene encodes otoferlin, a protein that enables the inner hair cells of the cochlea to release neurotransmitter vesicles in response to stimulation by sound to activate auditory neurons. Most individuals with
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and .
VALNEVAApril 12, 2021 GMT
Saint-Herblain (France), April 12, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV) 1.